About ACEA Biosciences
ACEA Biosciences is a company based in San Diego (United States) founded in 2002 was acquired by Agilent in September 2018.. ACEA Biosciences has raised $37.89 million across 2 funding rounds from investors including Agilent, Qiming Venture Partners and Lilly Asia Ventures. The company has 5,968 employees as of December 31, 2021. ACEA Biosciences operates in a competitive market with competitors including Cytek Biosciences, Accuri Cytometers, Bioaffinity technologies, NanoFCM and Orflo, among others.
- Headquarter San Diego, United States
- Employees 5968 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of ACEA Biosciences
ACEA Biosciences has successfully raised a total of $37.89M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round round of $7.89 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Private Equity Round — $7.9M
-
First Round
First Round
(06 Nov 2015)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2018 | Amount | Private Equity Round - ACEA Biosciences | Valuation |
investors |
|
| Nov, 2015 | Amount | Private Equity Round - ACEA Biosciences | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ACEA Biosciences
ACEA Biosciences has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Agilent, Qiming Venture Partners and Lilly Asia Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are directed toward multiple sectors.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Diversified instruments are developed for scientific and laboratory management.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ACEA Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ACEA Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acea Biosciences Comparisons
Competitors of ACEA Biosciences
ACEA Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytek Biosciences, Accuri Cytometers, Bioaffinity technologies, NanoFCM and Orflo, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Advanced flow cytometry systems are manufactured for research applications.
|
|
| domain | founded_year | HQ Location |
Compact flow cytometers for cell analysis are developed and provided.
|
|
| domain | founded_year | HQ Location |
IVD platforms are developed to detect and target cancer cells.
|
|
| domain | founded_year | HQ Location |
Offers advanced tools for nanoparticle analysis in biotechnology and healthcare.
|
|
| domain | founded_year | HQ Location |
Instrumentation for cell and protein analysis is developed and marketed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acea Biosciences
Frequently Asked Questions about ACEA Biosciences
When was ACEA Biosciences founded?
ACEA Biosciences was founded in 2002 and raised its 1st funding round 13 years after it was founded.
Where is ACEA Biosciences located?
ACEA Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is ACEA Biosciences a funded company?
ACEA Biosciences is a funded company, having raised a total of $37.89M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $30M, raised on Nov 06, 2015.
How many employees does ACEA Biosciences have?
As of Dec 31, 2021, the latest employee count at ACEA Biosciences is 5,968.
What does ACEA Biosciences do?
Founded in 2002 in San Diego, United States, instruments for life science research are developed by ACEA Biosciences. Operations focus on non-invasive technologies, including xCELLigence Real-Time Cell Analysis systems that utilize gold microelectrodes for label-free cell-based assays in multiwell formats. Additionally, the NovoCyte Flow cytometer is marketed to support high-throughput flow cytometry in research settings.
Who are the top competitors of ACEA Biosciences?
ACEA Biosciences's top competitors include Cytek Biosciences, Bioaffinity technologies and Accuri Cytometers.
Who are ACEA Biosciences's investors?
ACEA Biosciences has 3 investors. Key investors include Agilent, Qiming Venture Partners, and Lilly Asia Ventures.